DIRECTORS
Arthur L. Rosenthal, CEO Cappella Inc. & Chair, Interface Biologics
Dr. Rosenthal is currently CEO of Cappella, Inc., a medical device company focused on coronary artery disease. He has previously served as Chairman and CEO of Labcoat Ltd. (Galway, Ireland), Senior Vice President and Chief Scientific Officer of Boston Scientific Corporation, VP of Research & Development for Johnson & Johnson Medical and VP Research & Development at CR Bard. He has been Chairman, Industrial Advisory Board, Department of Biomedical Engineering, Boston University and Adjunct Professor, Translational Biomedical Engineering, Boston University, Dept of Biomedical Engineering. Art has served as Director on Renovo, Ltd., UK (Non Executive Director, Chairman, Remuneration Committee), Labcoat Ltd., Ireland (Chairman, BOD) Cyberonics, Inc, Houston, Tx,,(Non Executive Director, Chairman, Compensation Committee Dr. Rosenthal received his Ph.D. in Biochemistry from the University of Massachusetts.
Denis Ho, Managing Director of Life Sciences, BDC Venture Capital
Mr. Ho joined BDC Venture Capital in 2003 as Managing Director, Life Sciences. Denis has over 20 years of experience in the North American financial markets including MDS Capital Corp as venture partner, Forbes Capital Canada Inc. as partner, KPMG as partner and Mercantile Bank of Canada as account manager. Denis holds an MBA from University of Western Ontario, M.Sc. in Medical Microbiology from Queen's University and a B.Sc., from the University of Toronto.
Lily Lam, Vice President, Investments, Covington Capital Partners
Lily joined Covington in November 2000. Her responsibilities include assessing new business opportunities, negotiating and structuring transactions and actively advising investee companies in a variety of sectors including healthcare, media, software and service. Prior to joining Covington, Lily held various management positions within several early-stage healthcare companies where she provided expertise in finance, operations and strategic direction. Lily holds an MBA from York University and an M.Sc. from the University of Toronto. She currently sits as a Director on the Boards of BTE Technologies Inc., Insception Biosciences Inc. and Bedlam Games.
Cynthia Lavoie, Director with VG Partners
Dr. Lavoie is currently a Director with VG Partners, Part of VenGrowth Private Equity Partners Inc. Cynthia works closely with company management lending her technical and financial expertise to operations as well as financing, merger and exit transactions. She has been with the firm for over seven years and is currently on the boards of, Aegera Therapeutics, Axela, Cytochroma, Interface Biologics Trillium Therapeutics and Zelos Therapeutics. Cynthia’s prior experience includes positions as Investment Manager with the OGI where she initiated a seed financing program and as Marketing Strategy Consultant with Vasogen, a medical device and therapeutics company (merged with Intellipharmaceutics). Cynthia is an accomplished academic with over ten years of research experience having completed her Ph.D. (honours) at McGill University in Molecular and Cellular Biology and a fellowship at the UT Southwestern Medical Center. Cynthia also holds an MBA from the University of Toronto Rotman School of Management.
Leonard Pinchuk, Ph.D., D.Sc.
Dr. Pinchuk received a B.S. degree in Chemistry from McGill University in 1976 and a Ph.D. in the fields of Engineering, Chemistry and Medicine from the University of Miami in 1984. He was awarded a Doctor of Science honoris causa degree from McGill University in 2005.
Dr. Pinchuk is an inventor and entrepreneur in the field of biomaterials and medical devices with over 80 patents in this area. In addition to founding or co-founding five start-up companies, his accomplishments include the invention of the nylon angioplasty balloon, the world’s most widely used angioplasty catheter; a family of polycarbonate urethane biomaterials for implantation applications; polyurethane-based vascular grafts and stent-grafts; and the use of the novel biomaterial “SIBS” for long-term implantation applications. These SIBS formulations have contributed to the development and success of several implantable devices.
After beginning his career in 1983 at Cordis Corporation in Miami, Florida, Dr. Pinchuk left to co-found Corvita Corporation where he pioneered the field of stent-grafts. Corvita was merged with Pfizer’s Schneider AG division which was then purchased by Boston Scientific Corporation in 1998. Later, Dr. Pinchuk founded Innovia LLC and later, InnFocus LLC and InnoGraft LLC. Innovia is developing a new family of polymers for synthetic heart valves, spinal implants, breast implants and other medical applications. InnFocus and InnoGraft are developing products in the field of ophthalmology and vascular grafts, respectively. Much of this work relies upon collaboration with universities and thus Dr. Pinchuk is involved with technology transfer departments, grants and contracts related to biomedical research and development.
Thomas P. Reeves, President & CEO
Mr. Reeves is President and CEO of Interface Biologics. A more detailed description of his credentials is included in the "Our Management" section of this website.
Paul Santerre, Ph.D., Chief Scientific Officer, Interface Biologics Inc.
Dr. Santerre is the founder and Chief Scientific Officer of Interface Biologics and a full professor of biomaterials at the University of Toronto. A more detailed biography is included in the “Our Management” section of this website.